Trending menu:
News
-
12 November 2019
AstraZeneca’s anifrolumab shows promise in trial for SLE
AstraZeneca has reported that anifrolumab reduced disease activity in the Phase III TULIP 2 study involving patients with moderate to severe systemic lupus erythematosus (SLE).
-
12 November 2019
Janssen’s Tremfya meets primary endpoint in Discover studies
Janssen Pharmaceutical has reported positive data from the Phase III Discover-1 and Discover-2 clinical trials of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA).
-
12 November 2019
Roche and PTC report positive data for risdiplam in SMA
Roche and PTC Therapeutics have reported positive results from the second part of the SUNFISH trial of risdiplam to treat spinal muscular atrophy (SMA).
-
11 November 2019
ClinOne and Boston Children’s Hospital partner for trial enhancement
ClinOne has launched its eConsent with Video eConsent technology in collaboration with Boston Children’s Hospital (BCH).
-
11 November 2019
Alnylam begins Phase III trial of lumasiran in PH1
Alnylam Pharmaceuticals has initiated a Phase III clinical trial of its RNAi therapeutic, lumasiran, to treat patients with primary hyperoxaluria type 1 (PH1).
-
11 November 2019
Genentech’s Gazyva improves renal response in lupus nephritis patients
Roche subsidiary Genentech has reported improved complete renal response (CRR) in proliferative lupus nephritis patients treated with Gazyva (obinutuzumab) in a Phase II NOBILITY clinical trial.
-
11 November 2019
Daiichi Sankyo’s Phase III trial of esaxerenone meets primary goal
Daiichi Sankyo has reported positive data from the Phase III clinical trial of esaxerenone to treat patients with incipient diabetic nephropathy, which is type 2 diabetes with microalbuminuria, in Japan.
-
8 November 2019
TrialAssure launches document anonymisation tool using AI
Clinical trial transparency tools provider TrialAssure has launched new software called Anonymize R.
-
8 November 2019
EIP Pharma reports mixed results from neflamapimod Alzheimer’s trial
EIP Pharma has reported data from the Phase IIb REVERSE-SD clinical trial of brain-penetrant drug neflamapimod in patients suffering from early-stage Alzheimer’s disease.
-
8 November 2019
ObsEva plans to halt clinical programme of IVF nolasiban drug
Biopharmaceutical firm ObsEva will end the current clinical development programme of nolasiban IVF after the drug failed in the Phase III IMPLANT 4 clinical trial in Europe.